A novel chimeric phage lysin with high <i>in vitro</i> and <i>in vivo</i> bactericidal activity against <i>Streptococcus pneumoniae</i>

Abstract

Domain swapping among phage lysins allows the construction of new chimeric enzymes with high bactericidal activity and a different substrate range. Cpl-711, the most powerful endolysin against pneumococci, offers a promising therapeutic perspective for the treatment of multiresistant pneumococcal infections.